Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK372475 vs Paroxetine in MDD
NCT00420641Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2006
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of NS2359 in major depressive disorder (MDD), sponsored by GSK. Started Dec 2006; status: completed.
02
Drugs
NS2359
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00420641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00420641.